Publications by authors named "Giulia Quaresmini"

Claim this Profile
V
Venetoclax therapy in chronic lymphocytic leukaemia patients relapsed after allogeneic haematopoietic stem cell transplantation.
Francesca Perutelli, Elia Boccellato, Maria Chiara Montalbano, Gioacchino Catania, Marina Deodato, Giulia Quaresmini

Br J Haematol· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Atezolizumab, venetoclax, and obinutuzumab combination in Richter transformation diffuse large B-cell lymphoma (MOLTO): a multicentre, single-arm, phase 2 trial.
Alessandra Tedeschi, Anna Maria Frustaci, Adalgisa Condoluci, Marta Coscia, Roberto Chiarle, Giulia Quaresmini

Lancet Oncol· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Molecular prognostication for transplant decision making of patients with myelodysplastic syndromes: A retrospective single-center study.
Annalisa Condorelli, Marco Frigeni, Giulia Quaresmini, Silvia Salmoiraghi, Chiara Pavoni

Leuk Res· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rapid immune reconstitution following the infusion of autologous, Blinatumomab Expanded T-cells (BET) in patients with B-cell indolent NHL or CLL.
Giuseppe Gritti, Silvia Ferrari, Federico Lussana, Anna Maria Barbui, Francesco Landi, Giulia Quaresmini

Blood Cancer J· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lymphadenopathy as a predictor of progression during venetoclax treatment in chronic lymphocytic leukemia. A campus chronic lymphocytic leukemia study.
Francesco Autore, Idanna Innocenti, Gianluigi Reda, Andrea Visentin, Candida Vitale, Giulia Quaresmini

Hematol Oncol· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The evolving landscape of COVID-19 and post-COVID condition in patients with chronic lymphocytic leukemia: A study by ERIC, the European research initiative on CLL.
Andrea Visentin, Thomas Chatzikonstantinou, Lydia Scarfò, Anargyros Kapetanakis, Christos Demosthenous, Giulia Quaresmini

Am J Hematol· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
How COVID-19 pandemic changed our attitude to venetoclax-based treatment in chronic lymphocytic leukemia.
Marina Deodato, Anna Maria Frustaci, Paolo Sportoletti, Luca Laurenti, Roberta Murru, Giulia Quaresmini

Leuk Lymphoma· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Thrombotic and bleeding complications in patients with chronic lymphocytic leukemia and severe COVID-19: a study of ERIC, the European Research Initiative on CLL.
Darko Antic, Natasa Milic, Thomas Chatzikonstantinou, Lydia Scarfò, Vladimir Otasevic, Giulia Quaresmini

J Hematol Oncol· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study.
Thomas Chatzikonstantinou, Anargyros Kapetanakis, Lydia Scarfò, Georgios Karakatsoulis, David Allsup, Giulia Quaresmini

Leukemia· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Management of chronic lymphocytic leukemia in Italy during a one year of the COVID-19 pandemic and at the start of the vaccination program. A Campus CLL report.
Antonio Cuneo, Gian Matteo Rigolin, Marta Coscia, Giulia Quaresmini, Lydia Scarfò

Hematol Oncol· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus.
Lydia Scarfò, Thomas Chatzikonstantinou, Gian Matteo Rigolin, Giulia Quaresmini, Marina Motta

Leukemia· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Update of the GIMEMA MDS0306 study: Deferasirox for lower risk transfusion-dependent patients with myelodysplastic syndromes.
Alfonso Piciocchi, Valeria Sargentini, Francesca Cotugno, Katia Bontempi, Germana Beltrami, Giulia Quaresmini

Eur J Haematol· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
FarmaREL: An Italian pharmacovigilance project to monitor and evaluate adverse drug reactions in haematologic patients.
Nicola S Fracchiolla, Silvia Artuso, Agostino Cortelezzi, Anna M Pelizzari, Paola Tozzi, Giulia Quaresmini

Hematol Oncol· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Health-related quality of life in transfusion-dependent patients with myelodysplastic syndromes: a prospective study to assess the impact of iron chelation therapy.
Fabio Efficace, Valeria Santini, Giorgio La Nasa, Francesco Cottone, Carlo Finelli, Giulia Quaresmini

BMJ Support Palliat Care· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The influence of disease and comorbidity risk assessments on the survival of MDS and oligoblastic AML patients treated with 5-azacitidine: A retrospective analysis in ten centers of the "Rete Ematologica Lombarda".
Alfredo Molteni, Marta Riva, Lorenza Borin, Massimo Bernardi, Anna Maria Pelizzari, Giulia Quaresmini

Leuk Res· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase II multi-center trial of pentostatin plus cyclophosphamide with ofatumumab in older previously untreated chronic lymphocytic leukemia patients.
Alessandra Tedeschi, Davide Rossi, Marina Motta, Giulia Quaresmini, Marianna Rossi

Haematologica· December 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A novel method using blinatumomab for efficient, clinical-grade expansion of polyclonal T cells for adoptive immunotherapy.
Josée Golay, Anna D'Amico, Gianmaria Borleri, Michela Bonzi, Rut Valgardsdottir, Giulia Quaresmini

J Immunol· November 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Deferasirox for transfusion-dependent patients with myelodysplastic syndromes: safety, efficacy, and beyond (GIMEMA MDS0306 Trial).
Emanuele Angelucci, Valeria Santini, Anna Angela Di Tucci, Giulia Quaresmini, Carlo Finelli

Eur J Haematol· June 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of JAK2V617F mutation assessment employing different molecular diagnostic techniques.
Dino Veneri, Enrico Capuzzo, Giovanna de Matteis, Massimo Franchini, Elisabetta Baritono, Giulia Quaresmini

Blood Transfus· July 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Usefulness of the MSG/IFICG/EORTC diagnostic criteria of invasive pulmonary aspergillosis in the clinical management of patients with acute leukaemia developing pulmonary infiltrates.
Erika Borlenghi, Chiara Cattaneo, Maria Adele Capucci, Angelo Pan, Giulia Quaresmini

Ann Hematol· March 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis